The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 343:581-584 August 24, 2000 Number 8
NextNext

Kaposi's Sarcoma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Robertson, D.
-Related Article
 by Antman, K.
To the Editor: In their review of Kaposi's sarcoma, Drs. Antman and Chang (April 6 issue)1 thoroughly discuss the therapeutic options for advanced and aggressive Kaposi's sarcoma and conclude that "all the drugs studied so far have clinically significant systemic side effects." Treatment options for cases of less severe disease were omitted from the discussion by Antman and Chang.

Until recently, the treatment of less severe cutaneous Kaposi's sarcoma has been limited to the destructive approaches of cryotherapy with liquid nitrogen and intralesional vinblastine. Although effective in the treatment of individual cutaneous lesions of Kaposi's sarcoma, these approaches are painful . . . [Full Text of this Article]

References




HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.